In our experience, without the use of colony-stimulating factors in the aforementioned patients, we have noted the occurrence of moderate neutropenia, occasionally necessitating treatment delays.

Management expects full enrollment in the Phase 3 4WARD trial for chronic neutropenia by Q3 or Q4 ... below 1,000 cells per microliter, addressing moderate to severe neutropenic participants.